No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
APLMW Apollomics
- 0.013
- +0.002+16.66%
Close Dec 20 16:00 ET
0.013High0.008Low
0.013High0.008Low30.45KVolume0.011Open0.011Pre Close349.00Turnover0.00%Turnover Ratio--P/E (Static)0Shares0.03052wk High--P/B0Float Cap0.00652wk Low--Dividend TTM0Shs Float0.030Historical High--Div YieldTTM41.99%Amplitude0.006Historical Low0.011Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
News
Express News | Apollomics Announces Top-Line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Express News | Apollomics Regains Compliance With Nasdaq’s Minimum Bid Price Requirement
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
Express News | Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Express News | Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients With Non-CNS Met Fusion Solid Tumors From Its Phase 2 Sparta Trial